The US Food and Drug Administration (FDA) has approved Lecanemab, a breakthrough drug to treat Alzheimer's, that is manufactured by biotechnology companies Biogen and Eisai.The drug is an intravenously administered humanized monoclonal antibody that targets amyloid, the toxic protein in the brain linked to the cognitive disease.
[
add
]
[
|
|
...
]